Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139.

Authors

Fatemeh Ardeshir-Larijani

Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN

Fatemeh Ardeshir-Larijani , Sandra K. Althouse , Ticiana Leal , Lawrence Eric Feldman , Taher Abu Hejleh , Malini Patel , Ryan D. Gentzler , Adam Ryan Miller , Nasser H. Hanna

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, +/- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked.

First Author: Joseph Nicholas Bodor

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).

First Author: Sehhoon Park

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.

First Author: Yuming Zhu

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).

First Author: Aaron Scott Mansfield